Remove Blood Clot Remove Defibrillator Remove Patient Care
article thumbnail

2024’s Mid-Year Review: FDA-Approved Cardiorenal Metabolic Drugs and Devices 

Cardiometabolic Health Congress

Staying informed about these cutting-edge developments is critical for providing exceptional patient care. Join us as we examine the landmark approvals that are revolutionizing patient outcomes. The label includes a “black box” warning for CV risk due to blood clots.